Clinical Trial Update: Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant PD-1 antibody plus apatinib or chemotherapy for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING